Promising results from the University of Pittsburgh APDA Center for Advanced Research

Promising results from the University of Pittsburgh APDA Center for Advanced Research Building off of pivotal APDA-funded work highlighted here, Dr. J. Timothy Greenamyre and his team, published a investigating the role of Leucine-rich Repeat Kinase (LRRK2) in the development of Parkinson’s disease (PD). LRRK2 is known to be mutated in a small percentage of […]

Read More

Taking Parkinson’s education to the farmers market: educating under-served communities

Taking Parkinson’s education to the farmers market: educating under-served communities Dr. Lynda Nwabuobi, Movement Disorder Fellow at Columbia Presbyterian Medical Center in New York City, attended APDA’s Diversity in Parkinson’s Disease (PD) Research Conference in May and was inspired. Dr. Nwabuobi  had just spent the day learning about health care disparities in PD care, low […]

Read More

New medication, Istradefylline, gets approved for Parkinson’s disease

New medication, Istradefylline, gets approved for Parkinson’s disease On August 27, 2019, pharmaceutical company Kyowa Kirin received FDA approval for Istradefylline, a new medication for Parkinson’s disease (PD) to be used as an add-on treatment to carbidopa/levodopa for those experiencing OFF episodes. (For more information on OFF periods in PD, please see this recent APDA […]

Read More

$52 billion per year is spent on PD-related expenses, according to results of the Economic Burden of Parkinson’s Disease Study

$52 billion per year is spent on PD-related expenses, according to results of the Economic Burden of Parkinson’s Disease Study In October 2018, APDA asked our constituents to consider participating in a new study called The Economic Burden of Parkinson’s Disease (PD), with the goal of estimating the economic burden of PD in the United […]

Read More

FDA Approves Inbrija™ (levodopa inhalation powder) Parkinson’s disease

FDA Approves Inbrija™ (levodopa inhalation powder) December 22, 2018 Acorda Therapeutics announced the FDA approval of INBRIJA™ (levodopa inhalation powder) for the treatment of OFF periods in people with Parkinson’s disease (PD) taking carbidopa/levodopa. INBRIJA™ is expected to be available by prescription in the first quarter of 2019, to be distributed through a network of specialty […]

Read More